Bayer shareholders are getting a token payout and a fresh set of boardroom faces, but the real action this week is in Washington, where the US Supreme Court is set to hear a case that could reshape the company’s multi-billion-dollar glyphosate liability.
The German drug and crop-chemicals group held its annual general meeting on Friday, approving a dividend of just €0.11 per share for the 2025 financial year — the legal minimum. The payout, scheduled for April 29, is part of a three-year austerity plan that prioritises debt reduction over investor returns. Chief executive Bill Anderson defended the strategy, arguing that every euro saved will be funnelled into the pharmaceuticals pipeline.
Anderson’s own future at the helm is now secured until March 2029, after the supervisory board extended his contract alongside that of pharma chief Stefan Oelrich. In the finance department, Dr Judith Hartmann takes over from Wolfgang Nickl at the end of May.
Restructuring Progress and Investor Patience
Since launching his “Dynamic Shared Ownership” overhaul, Anderson has cut roughly 14,000 jobs, with nearly 5,000 of those coming last year alone. The restructuring is far from finished, he told the virtual meeting, but early signs are encouraging.
Fund managers at Deka and Union Investment acknowledged the operational improvements but struck different notes on strategy. Deka pushed for an open-ended review of Bayer’s corporate structure — provided the US legal disputes are resolved first. Union Investment, by contrast, backed the current approach, preferring to keep the consumer health division inside the group for now.
The board also elected two new supervisory board members: Marcel Smits, former chief financial officer at Cargill, and Alfred Stern, chief executive of Austrian energy group OMV. Both bring deep experience in international industrial operations and strategic planning.
Should investors sell immediately? Or is it worth buying Bayer?
Profit Stagnation and Cash Flow Squeeze
For the current financial year, management has tempered expectations. Adjusted earnings per share are forecast to remain flat at constant exchange rates, as new product launches struggle to offset patent expirations in both the pharma and agriculture divisions. The group also expects negative free cash flow, weighed down by ongoing legal payouts.
The stock market took a dim view of the AGM’s outcome. Bayer shares fell nearly four percent on Friday to close at €38.50, slipping below their 100-day moving average. That leaves the stock roughly 22 percent below its 52-week high from February. The relative strength index stands at 46.8, and the price now trades beneath both medium-term averages.
Despite the recent weakness, the shares have still rallied about 70 percent over the past twelve months.
Supreme Court Holds the Key
The immediate catalyst comes on Monday, when the US Supreme Court hears oral arguments in the Durnell case, a proceeding that could determine how Bayer handles the remaining glyphosate-related lawsuits. A favourable ruling would provide significant relief; an adverse one could deepen the stock’s technical woes.
Analysts remain broadly constructive. JPMorgan maintains an “Overweight” rating with a fair value target of €50, while Goldman Sachs highlights the potential of the menopause drug Lynkuet in Bayer’s pharma pipeline.
The next major financial milestone is May 12, when Bayer publishes its first-quarter results for 2026. That report will show whether the operational restructuring is beginning to translate into the numbers — or whether the legal drag continues to hold the company back.
Ad
Bayer Stock: Buy or Sell?! New Bayer Analysis from April 25 delivers the answer:
The latest Bayer figures speak for themselves: Urgent action needed for Bayer investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from April 25.
Bayer: Buy or sell? Read more here...
